Regulated Healthcare Brand Name Checklist: Screening, FDA Submission, and Trademark Filing

By Casey Scott McKay · 2023-09-27

Sixteen phases for naming a regulated healthcare product, sequenced so candidates are eliminated before anyone becomes attached to them. Phase zero asks whether the product needs a brand name at all, which for many generics and devices it does not. The screening phases run six safety screens and a trademark knockout simultaneously across a long list of forty to sixty candidates, then present only survivors to the brand team - the single sequencing decision that prevents the failure mode costing most programs a year. Later phases cover the comparison set nobody builds properly, the submission package as an argument rather than a form, the three responses to a rejection and how to choose, the intent-to-use filings timed against the thirty-six-month wall and the Section 44 structure that solves it, and the maintenance and enforcement work that continues after launch.

IP and Technology > Trademarks | Checklist | Published 27 September 2023 - Updated 7 August 2026 | Casey Scott McKay - marksy.us

Summary. Sixteen phases for naming a regulated healthcare product, sequenced so candidates are eliminated before anyone becomes attached to them. Phase zero asks whether the product needs a brand name at all, which for many generics and devices it does not. The screening phases run six safety screens and a trademark knockout simultaneously across a long list of forty to sixty candidates, then present only survivors to the brand team — the single sequencing decision that prevents the failure mode costing most programs a year. Later phases cover the comparison set nobody builds properly, the submission package as an argument rather than a form, the three responses to a rejection and how to choose, the intent-to-use filings timed against the thirty-six-month wall and the Section 44 structure that solves it, and the maintenance and enforcement work that continues after launch.

Keywords: naming brief · cross-functional naming group · long list screening · orthographic phonetic analysis · first three characters · promotional implication · stem collision · dosing abbreviation confusion · cross-language screening · simulated prescription study · submission package · rejection response · class 5 clearance · deadwood expungement · identification drafting · intent to use timing · thirty-six month wall · section 44 basis · madrid designation · post-launch maintenance

What this checklist is for

This is the working document for naming a drug, biologic, or device. It does not re-teach the regime. If you cannot say in one sentence why a name that is a strong trademark is frequently a weak regulatory candidate, read The Name the FDA Has to Approve first. The reasoning behind each box is in Clearing a Pharmaceutical or Device Brand Name. This document tells you what to do, in order.

Who should use it. Trademark counsel supporting a development program; regulatory counsel who owns the submission; the brand lead who will run the naming project; medication safety and pharmacovigilance colleagues; and diligence counsel evaluating a pharmaceutical brand in a transaction.

What you'll need before you start. The product's essential characteristics — established name, dosage forms, strengths, route, indication, patient population, and care setting; the development timeline and expected approval date; the launch market list; the brand architecture, if line extensions are contemplated; the sponsor's existing portfolio; and a naming agency briefed on the constraints before it generates anything.

The worked matter. Verrant Therapeutics, an oral agent for a chronic inflammatory condition, with a favored candidate CALMIRA — which clears a trademark knockout in Class 5 and fails screen three, because "CALM" implies a therapeutic effect the labeling will not claim.

| Phase | What you accomplish | Typical elapsed time | |---|---|---| | 0 | Decide whether a brand name is needed | 1 week | | 1 | Write the brief and build the group | 1-2 weeks | | 2 | Brief the naming agency on the constraints | 3 days | | 3 | Build the comparison set | 1-2 weeks | | 4 | Generate the long list | 2-3 weeks | | 5 | Run the six safety screens | 3-5 weeks | | 6 | Run the trademark knockout in parallel | 2-3 weeks | | 7 | Present survivors; let the brand team rank | 1 week | | 8 | Full clearance on the shortlist | 3-6 weeks | | 9 | Draft the identification of goods | 1 week | | 10 | Time the intent-to-use filings | 2 weeks | | 11 | File internationally | 8-16 weeks | | 12 | Commission the simulated study | 6-10 weeks | | 13 | Build and file the submission package | 4-6 weeks | | 14 | Respond to a rejection | 2-8 weeks | | 15 | Handle device, OTC, and other variants | as applicable | | 16 | Maintain, enforce, and monitor after launch | ongoing |

Phase 0 — Decide whether a brand name is needed

[ ] Ask the commercial team: who chooses this product, on what basis, and would a brand name change that choice?
[ ] Where the answer is a formulary committee selecting on price and supply reliability, the brand name is a cost with no return. Many generics and biosimilars are marketed under the nonproprietary name plus the company name, with no invented brand.
[ ] Consider the intermediate structures: a house brand plus the nonproprietary name, cleared once and used across a portfolio; or a product family on a shared root, adopted deliberately rather than by drift.
[ ] For devices, apply the same question. A company with forty SKUs and forty invented names has forty clearance obligations and forty maintenance dockets.
[ ] Where the answer is no, run an ordinary trademark program on the corporate mark and any house brand. See Trademark Clearance and Brand Selection Toolkit.

Phase 1 — Write the brief and build the group

[ ] Write the brief before any candidate exists: what the name must do commercially; what markets it must work in; what the brand architecture requires; what it must avoid regulatorily; and the agreed standard for "good enough."
- Why. It prevents the argument at the end about whether a surviving candidate is acceptable, because the standard was agreed when nobody had a favorite.
[ ] Build a single cross-functional group from the long-list stage: brand and commercial; regulatory affairs; medication safety or pharmacovigilance; trademark counsel; regulatory counsel; and the naming agency.
- Trap. The failure mode is the brand team running the project, presenting a favorite, and consulting legal and regulatory to confirm it. By then the conversation is about saying no.
[ ] Name the substitution decision-maker now.
- Why. After a rejection, someone must decide within days whether to reconsider, modify, or substitute. Assembling a committee to decide costs six weeks the program does not have.

Phase 2 — Brief the naming agency on the constraints

[ ] Give the agency the regulatory constraints before it generates.
[ ] Ask specifically for a proportion of the long list to be non-suggestive coinages with no discernible root meaning.
- Why. Agencies build long lists from morphemes that suggest benefits, which is exactly what screen three eliminates. Non-suggestive coinages survive both processes, brand teams like them least on first hearing, and they become recognizable brands after a launch campaign.
- The instruction worth giving in one line. A name that explains itself will not be approved.

Phase 3 — Build the comparison set

[ ] Assemble the universe against which candidates will be compared: currently marketed products in the relevant and adjacent therapeutic areas; products marketed in the launch markets abroad; discontinued products still in circulation or in prescriber memory; publicly disclosed pipeline names; and the sponsor's own portfolio.
[ ] Weight by therapeutic proximity. Similarity to a product a patient might plausibly take at the same time, or that a prescriber selects from the same dropdown, is a larger risk than similarity to a product in an unrelated field with a different route and care setting.
[ ] Add a consequence dimension. A name similar to another antihypertensive and a name similar to a chemotherapy agent are different risks at identical similarity scores, because the harm from an error differs by orders of magnitude.
[ ] Run the internal look-alike check twice: against the current portfolio, and against every candidate still live in the sponsor's other naming programs.
- Why. Two programs at the same company selecting adjacent names is foreseeable, preventable, and it happens.

Phase 4 — Generate the long list

[ ] Generate forty to sixty candidates. More than a brand team wants to review, which is the point.
[ ] Do not show the list to the brand team yet.

Phase 5 — Run the six safety screens

[ ] Screen one — orthographic. Shared letter sequences, overall shape, length, and confusable letter pairs in handwriting. Weight the first three characters heavily, because they drive order-entry selection and shelf ordering.
[ ] Screen two — phonetic. How the name sounds degraded over a phone line, across regional accents, and spoken quickly.
[ ] Screen three — promotional implication. Read every morpheme and ask what a clinician or patient would understand it to claim. Roots suggesting speed, strength, purity, cure, restoration, or an organ system are objection candidates, and so are the less obvious Latin and Greek roots the agency chose because they suggest a benefit. 21 U.S.C. § 352; 21 C.F.R. § 201.10.
[ ] Screen four — stem collision. Check against recognized nonproprietary stem lists. See USAN program; WHO INN programme.
[ ] Screen five — dosing and abbreviation confusion. Does any element read as a number, unit, route, or medical abbreviation? "QD," "IV," "MG," or a numeral can be misread as a dosing instruction.
[ ] Screen six — cross-language. Meaning, pronounceability, and connotation in every launch market, and against marketed names there — because the European invented-name review applies comparable criteria on its own timetable. See EMA invented name review.
[ ] Document each screen per candidate: what was compared, what was found, and why the candidate survived or did not.
- Why three reasons. It supports the submission; it prevents re-litigating an eliminated candidate when a senior stakeholder rediscovers it in month nine; and it is the record showing the sponsor took medication safety seriously if an error occurs post-launch.
[ ] Use computational similarity tools to build the comparison list, not to make the decision.
- Trap. They produce false positives and false negatives in both directions. A mediocre algorithmic score with an obvious human-perceptible difference is a different case from the same score with none.

Phase 6 — Run the trademark knockout in parallel

[ ] Knockout in Class 5 and the relevant device classes, simultaneously with Phase 5, eliminating on both grounds at once.
[ ] See Trademark Clearance Searching.

Phase 7 — Present survivors; let the brand team rank

[ ] Present eight to twelve survivors to the brand team for the first time.
[ ] Let the brand team rank them.
- Why this sequencing matters more than anything else in this checklist. A brand team that first sees candidates which have already survived both screens is choosing among viable options. A brand team that chooses first and screens second is being told no, and that is where programs lose a year.

Verrant, Phase 7. CALMIRA would have been eliminated at screen three, and probably at screen one, in week one — before the brand team saw it. The same conclusion reached in month eighteen costs a launch window.

Phase 8 — Full clearance on the shortlist

[ ] Full clearance on the top four or five.
[ ] Expect Class 5 to be crowded and the confusion analysis to be strict. 15 U.S.C. § 1052(d).
- Why. A mark that would coexist comfortably in Class 25 draws a refusal in Class 5, because confusion here has health consequences.
[ ] Assess the deadwood. Where a candidate is blocked by a registration for a product never marketed, the administrative route is cheaper than argument: expungement under 15 U.S.C. § 1066a or reexamination under § 1066b. See Cleaning the Register; Filing an Expungement or Reexamination Petition.
[ ] Check descriptiveness under 15 U.S.C. § 1052(e) and deceptiveness under § 1052(a).
- Note the opposing pressures. The USPTO objects because a name describes the goods; the FDA objects because it claims too much. A name surviving both suggests without describing and evokes without promising. See The Section 2 Bars; Overcoming a Section 2 Refusal.
[ ] Search common law and the foreign registers for every launch market.
[ ] See Running a Full Trademark Clearance Search; Trademark Clearance Search Checklist.

Phase 9 — Draft the identification of goods

[ ] Identify the therapeutic area rather than the specific approved indication.
- Why. Specific enough to distinguish the goods from unrelated pharmaceuticals, which narrows the confusion analysis in the applicant's favor; broad enough that a later indication expansion does not fall outside the registration.
[ ] Cover the device classes where the program includes a delivery device or companion diagnostic.
[ ] Remember an identification cannot be broadened after filing.
[ ] See Drafting an Identification of Goods and Services.

Phase 10 — Time the intent-to-use filings

[ ] File under 15 U.S.C. § 1051(b), because the mark cannot be used before approval.
[ ] Calendar the wall: statement of use due six months after allowance, extendable in six-month increments to thirty-six months from the notice of allowance. 15 U.S.C. § 1051(d).
[ ] Choose among four techniques: file later, accepting priority risk; file a family, so a rejection does not restart the clock; refile with a new priority date; or use a foreign basis under Section 44(d) or 44(e), which can produce a U.S. registration without proof of use.
- Why the foreign basis is underused. It is the cleanest answer to the structural collision between the two clocks, and sponsors file domestically first out of habit. See Filing on a Foreign Basis.
[ ] Diarize every extension deadline across the candidate portfolio, and decide at each whether the candidate is still live.
- Trap. Paying extensions on a rejected name is a recurring, avoidable cost.
[ ] See Intent-to-Use Applications; From Notice of Allowance to Registration; Statement of Use Filing Checklist.

Phase 11 — File internationally

[ ] Use Madrid for the bulk, noting central attack during the dependency period and specification limitations in some designated countries. See How Madrid Works; Madrid Protocol Filing; Designating Countries; Madrid Application Checklist.
[ ] Use national filings where Madrid is inadequate or the market is a known squatting risk.
[ ] Run an anti-squatting program in first-to-file markets, filed early and defensively. See First to File Wins; Building an International Filing and Anti-Squatting Program.
[ ] Sequence against the European invented-name review, because a name clearing in the United States and failing in Europe forces the same portfolio decision from the other direction.

Phase 12 — Commission the simulated study

[ ] Commission for the lead candidate only, where it has survived all six screens, matters commercially, and sits near enough to other names that a confusion concern is plausible.
[ ] Design it around real conditions: practitioners writing, reading, and transcribing the name alongside plausible confusers, with handwritten orders, verbal orders, and order-entry selection.
[ ] Budget $40,000 to $120,000 and six to ten weeks.
- Why it is worth it for one candidate. It is the strongest evidence available on the confusion question and the only evidence the sponsor generates rather than argues.

Phase 13 — Build and file the submission package

[ ] The proposed name, with pronunciation, derivation, and intended meaning stated plainly.
- Trap. An unexplained coinage invites the reviewer to supply their own reading of what it implies.
[ ] The product's essential characteristics: established name, dosage forms, strengths, route, indication, population, and care setting.
[ ] The sponsor's own similarity analysis, with the comparison set, the method, and the results — including the near misses and why they were judged acceptable.
- Why include them. Presenting only favorable results is transparent and undermines everything else in the package.
[ ] The promotional-implication analysis, morpheme by morpheme, against the labeling language.
[ ] The stem analysis, confirming no collision.
[ ] The simulated study, where one was run.
[ ] Labeling and packaging mock-ups, because the name is evaluated as it will appear, and a design where the proprietary name dominates and the established name is minimized creates a problem the name itself does not have. 21 C.F.R. § 201.10; 21 C.F.R. § 202.1.
[ ] A statement of any prior submission of the same or a similar name, and its outcome.
[ ] Write for a reviewer whose job is patient safety, not brand strategy — the commercial rationale is irrelevant and reads as advocacy.
[ ] Address the obvious objection directly rather than hoping it will not be raised.
[ ] Submit at a point in development where a first answer still leaves room to iterate. 21 C.F.R. § 314.50; 21 U.S.C. § 355. See FDA guidance on proprietary name submissions; FDA proprietary name guidance.

Phase 14 — Respond to a rejection

[ ] Treat it as expected, budgeted, and staffed — not as a crisis.
[ ] Read the basis. A confusion finding identifies the products of concern, which tells you what part of the name-space is closed. A promotional finding identifies the implication, which usually means a modest modification will not cure it.
[ ] Choose among three responses.
- Reconsideration with additional information — the simulated study, a distinguishing analysis of the cited products' dosage forms and routes, or evidence about the clinical settings. Works better against a confusion finding.
- Modification. A character or syllable can resolve an orthographic concern; it rarely resolves a promotional one, because the implication lives in the root the brand team chose deliberately.
- Substitution. The fastest path, the reason the portfolio exists, and the right answer more often than sponsors accept.
[ ] Note that reconsideration and resubmission each consume a review period.
[ ] Decide at this moment whether to keep paying extensions on the rejected candidate's application.
[ ] Remember approval is not permanent: a name can be revisited if labeling changes materially, a confusingly similar product enters the market, or post-marketing reports show errors. See Changing the Name on the Door; Executing a Rebrand.

Phase 15 — Handle device, OTC, and other variants

[ ] Devices. No formal proprietary name review, but 21 U.S.C. § 352 misbranding applies, the name appears in the 510(k) or premarket approval application and in labeling under 21 C.F.R. Part 801, and the enforcement mechanism is a warning letter after launch. Run screen three against the indications for use, rigorously, and document it.
[ ] Combination products are assigned to a lead center by primary mode of action; a drug-led product faces full review.
[ ] OTC monograph drugs. No application-based name review, but labeling and misbranding rules apply in full and the promotional analysis is more consequential because a consumer selects without a clinician.
[ ] Dietary supplements. Regulated as foods — but a name implying diagnosis, treatment, cure, or prevention of a disease converts the product into an unapproved drug.
[ ] Biologics. Licensed under 42 U.S.C. § 262, with an assigned nonproprietary suffix alongside the proprietary name.
[ ] Line extensions. A shared root plus a modifier is a recognized medication-error source. Expect scrutiny and expect the modifier to be evaluated on its own.
[ ] Compounded and unapproved products. A proprietary-sounding name raises whether the product is being marketed as an approved drug, which is an enforcement problem rather than a naming one.

Phase 16 — Maintain, enforce, and monitor after launch

[ ] File the statement of use promptly after first commercial use. 15 U.S.C. § 1051(d).
[ ] Docket Section 8 and Section 9 filings, 15 U.S.C. § 1058 and § 1059, and the equivalents abroad, on a docket that survives the departure of whoever set it up.
[ ] Abandon the unused candidates rather than paying maintenance indefinitely.
[ ] Watch for the category's specific infringement pattern: counterfeit product; unauthorized online pharmacies; parallel imports with different labeling; and domains imitating the brand for phishing or illicit sales. See Brand Enforcement Toolkit; Stopping Counterfeits at the Border; Fighting or Defending Parallel Imports; Building a Domain Name Portfolio and Enforcement Program.
[ ] Monitor pharmacovigilance data for name-related error signals.
- Why. A sponsor watching its own data is in a far better position than one that learns of the pattern from the Agency, and the remedies short of a name change — packaging redesign, tall-man lettering, prescriber communications, order-entry changes — are what a sponsor can offer instead.
[ ] Keep the file — screening record, submission package, correspondence, clearance opinions — in one place, because it will be requested in a transaction, in a regulatory interaction, and, if an error occurs, in litigation.
[ ] Run the transaction checks when the brand moves: goodwill must travel with the mark, 15 U.S.C. § 1060(a); an intent-to-use application generally may not be assigned before a statement of use except to a successor to the business; and co-promotion requires a real license with quality control, 15 U.S.C. § 1127. See Drafting a Trademark License That Survives; Trademark Due Diligence Checklist; Trademarks in the Deal.

Phase 12A — Budget and schedule the program

[ ] Present the whole program as one number with a schedule, not as a series of requests.

| Step | Elapsed | Cost | |---|---|---| | Brief, group formation, agency briefing | 2-3 weeks | $10k-$30k | | Comparison set construction | 1-2 weeks | $8k-$25k | | Long list generation | 2-3 weeks | agency fee | | Six safety screens | 3-5 weeks | $30k-$90k | | Trademark knockout across the list | 2-3 weeks | $8k-$25k | | Full clearance, per shortlisted candidate | 3-6 weeks | $12k-$40k each | | Simulated prescription study, lead candidate | 6-10 weeks | $40k-$120k | | Submission package and review support | months | $25k-$80k | | Intent-to-use filings, portfolio of four | 2 weeks | $6k-$18k plus fees | | Extension requests over the program | ongoing | $2k-$6k per name per cycle | | International filings, thirty jurisdictions | 8-16 weeks | $60k-$200k | | Substitution after a rejection | 3-6 months | $50k-$180k | | Annual maintenance and enforcement | ongoing | $40k-$140k/yr | | Post-approval name change | 12-24 months | $2M-$20M+ |

[ ] Give the program the total: $250,000 to $700,000 over several years, including one substitution.
- The framing that gets it approved. Large against a consumer branding project; trivial against a development program; a rounding error against the last row.
[ ] Distinguish the one-time rows from the perpetual ones when presenting. Maintenance and enforcement are annual and are the line cut in a budget review because nothing appears to be happening. Present them as portfolio maintenance tied to the products they protect.
[ ] Build the schedule backward from the expected approval date, marking: the latest date a first submission still leaves room to iterate; the date the thirty-six-month wall arrives for each filed candidate; the launch-market filing deadlines; and the European review timetable.
[ ] Add one contingency line the program will actually need: a second naming cycle, at three to six months and $50,000 to $180,000. A schedule with no substitution slot is a schedule that will slip.

Phase 16A — Diligence: evaluating someone else's pharmaceutical brand

When a brand arrives in a transaction rather than from a naming program, the questions are different and the answers are usually incomplete.

[ ] Registration coverage. Is the mark registered — not merely applied for — in every market on the commercial plan? Identify the gaps and price them, because a brand blocked in three of ten launch markets is a material finding.
[ ] Regulatory status. Is there an unresolved name objection, a conditional acceptance, or an open request for information? Ask for the full correspondence, not a summary.
[ ] Application status. Is any intent-to-use application within its extension window, and how many extensions remain? A candidate at month thirty of thirty-six is a problem the buyer inherits with a deadline attached.
[ ] Identification scope. Is the goods identification broad enough for the indications the buyer intends to pursue, or was it drafted narrowly to the initial approval?
[ ] Oppositions and refusals, pending or resolved, in every jurisdiction.
[ ] Use and maintenance. Has the mark been used in each jurisdiction in a way that supports maintenance, and are the Section 8 and 9 or equivalent filings current? 15 U.S.C. § 1058; 15 U.S.C. § 1059.
[ ] Chain of title, including whether goodwill travelled with any prior assignment, 15 U.S.C. § 1060(a), and whether any intent-to-use application was assigned before a statement of use.
[ ] Licenses and co-promotion agreements, and whether they contain real quality control. 15 U.S.C. § 1127.
[ ] Error signals. Any post-marketing reports associating the name with medication errors, and any communications with the Agency about them.
- Why this is the diligence item nobody requests. A name-associated error pattern is the precursor to a post-approval name change, which is the most expensive outcome in this entire checklist, and it is knowable from the seller's own pharmacovigilance data.
[ ] The screening file. Does it exist? Its absence tells you the seller never ran the analysis, which raises the probability of every risk above.
[ ] See Trademark Due Diligence Checklist; Trademark Due Diligence in Mergers and Acquisitions; IP Due Diligence Toolkit.

Key Authorities at a Glance

| Authority | What it provides | Phase | |---|---|---| | 21 U.S.C. § 352 | Misbranding | 5, 15 | | 21 U.S.C. § 355 | New drug applications | 13 | | 21 U.S.C. § 360c | Device pathways | 15 | | 42 U.S.C. § 262 | Biologics licensure | 15 | | 21 C.F.R. § 201.10 | Drug labeling; established name | 5, 13 | | 21 C.F.R. § 202.1 | Prescription drug advertising | 13 | | 21 C.F.R. § 314.50 | NDA content | 13 | | 21 C.F.R. Part 801 | Device labeling | 15 | | FDA proprietary name guidance | The criteria | 13 | | FDA submission guidance | Submission contents | 13 | | USAN program | Stems | 5 | | WHO INN programme | Global stems | 5 | | EMA invented name review | The European process | 5, 11 | | 15 U.S.C. § 1051(b) | Intent-to-use | 10 | | 15 U.S.C. § 1051(d) | Statement of use; thirty-six months | 10, 16 | | 15 U.S.C. § 1126 | Section 44 bases | 10 | | 15 U.S.C. § 1052(a) | Deceptive matter | 8 | | 15 U.S.C. § 1052(d) | Likelihood of confusion | 8 | | 15 U.S.C. § 1052(e) | Descriptiveness | 8 | | 15 U.S.C. § 1066a | Expungement | 8 | | 15 U.S.C. § 1066b | Reexamination | 8 | | 15 U.S.C. § 1058 | Section 8 maintenance | 16 | | 15 U.S.C. § 1059 | Renewal | 16 | | 15 U.S.C. § 1060(a) | Assignment limits | 16 | | 15 U.S.C. § 1127 | Naked licensing | 16 |

The five things people get wrong

Letting the brand team choose before the screens run. The single sequencing error that costs most programs a year, because a team that has invested in a name experiences the analysis as an obstacle rather than as information.

Briefing the naming agency without the constraints. Agencies build from morphemes that suggest benefits, which is precisely what the promotional screen eliminates. A name that explains itself will not be approved.

Carrying one candidate. A regulated naming program should assume it will name the product at least twice, and staff and budget accordingly.

Filing intent-to-use applications at candidate selection. The thirty-six-month wall arrives years before approval on a normal development timeline, and the Section 44 structure that solves it is available and underused.

Treating approval as the end. Maintenance, enforcement, and pharmacovigilance monitoring for name-related error signals continue for the life of the product, and a lapsed registration in a launch market is discovered at the worst possible moment.